University Medical Center Groningen (UMCG) — PsyPal trial site
Groningen, Netherlands
Treatment & access
- Treatments offeredPsilocybin
- Access routeTrial
- PricingNot published by this provider: contact them directly. What treatment costs and coverage look like in this country →
- Websitehttps://www.umcg.nl
Related listings
These records belong to the same organisation. They are listed separately because each is a distinct programme or location.
- Another programme at this clinicUMC Groningen (UMCG) : Spravato®
About this provider
Recruiting trials: NCT06782724 / EU CT 2023-510488-36-01: PsyPal: Psilocybin Therapy for Psychological Distress in Palliative Patients (sponsor: University Medical Center Groningen; EU Horizon-funded consortium; conditions: COPD, ALS, MS and atypical parkinsonism). Site status RECRUITING per ClinicalTrials.gov, checked 2026-09-07. UMCG also appears in the directory as an esketamine centre (separate record).
Services & programs
Programs & studies
| Program | Kind | Status |
|---|---|---|
| Clinical trial (NCT06782724) | clinical trial | Recruiting |
Verification
- License / registryPublic trial registry (ClinicalTrials.gov / EU CTIS)
- Official registryhttps://clinicaltrials.gov/study/NCT06782724
- Official registryhttps://euclinicaltrials.eu/ctis-public/view/2023-510488-36-01
- Last verified
Check your fit & enquire
Clinical trials access in Netherlands follows published criteria. A short pre-screening comes first, then your compiled summary goes to University Medical Center Groningen (UMCG) — PsyPal trial site only with your explicit consent, and you can download it for yourself either way.
Why enquire via PsyAccess
- Pre-screening first. A 2-minute check in your browser shows which legal routes fit your situation, before you reach out to anyone.
- A structured enquiry. Your enquiry reaches the provider with a structured summary, so the clinic can reply quickly and to the point.
- Independent & free. Free for patients. We don't charge for enquiries, and no provider pays for placement.